Importantly, preclinical and translational studies show that components of the IGFR-mediated pathway are implicated in SCCHN risk [15], angiogenesis [16], pharmacogenetics [17], [18], chemosensitivity [19], immunotherapy [20] and radiation response [21]. The gene discussed is IGF1R; the disease is head and neck squamous cell carcinoma.